fluorouracil and Biliary Tract Cancer
fluorouracil has been researched along with Biliary Tract Cancer in 146 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin." | 9.41 | A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. ( Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ, 2021) |
"We conducted a phase II trial of 5-fluorouracil and oxaliplatin combination chemotherapy as a second-line treatment in unresectable/metastatic biliary tract cancer patients who had failed gemcitabine-based chemotherapy." | 9.20 | Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. ( Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH, 2015) |
"Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects." | 9.17 | Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013) |
"The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 9.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
"This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients." | 9.16 | A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. ( Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V, 2012) |
"Many clinical trials have been conducted with gemcitabine- or 5-fluorouracil-based regimens as treatment for unresectable biliary tract cancer; however, the results remain unsatisfactory." | 9.16 | A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Sato, T; Sato, Y; Sonoda, T; Takimoto, R; Yoshida, M, 2012) |
"We conducted this phase II study in an effort to evaluate the efficacy and safety of a gemcitabine single chemotherapy as a second-line treatment for biliary tract cancer (BTC) patients who evidenced disease progression after the administration of 5-fluorouracil (5-FU)-based palliative chemotherapy." | 9.15 | Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. ( Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2011) |
"In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer." | 9.14 | Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010) |
"Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 9.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
"To evaluate the effects of palliative chemotherapy with gemcitabine plus capecitabine (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in patients with advanced biliary tract cancer." | 9.13 | Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. ( Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F, 2008) |
"This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas." | 9.13 | Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008) |
"The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer." | 9.12 | Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. ( Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS, 2007) |
"In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57." | 9.10 | Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003) |
"We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas." | 9.10 | Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002) |
"Gemcitabine-cisplatin (GP) has been regarded as standard first-line chemotherapy for advanced biliary tract cancer (BTC)." | 9.05 | Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis. ( Jin, J; Zhang, Y; Zheng, T; Zhou, L, 2020) |
"In this multicenter retrospective cohort analysis, we identified patients with metastatic biliary tract adenocarcinoma who were treated with Nal-IRI in combination with 5-fluorouracil and folinic acid following tumor progression under standard therapy at one of the study centers between May 2016 and January 2019." | 7.96 | First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. ( Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K, 2020) |
"The primary objective of this study was to determine the activity and safety of 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine in the first-line treatment of advanced biliary tract cancer." | 7.81 | Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. ( Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G, 2015) |
"The aim of this retrospective study was to investigate the relationship between UGT1A1 polymorphisms and toxicities in Chinese patients with pancreatic or biliary tract cancer receiving irinotecan-containing regimens as the second- or third-line chemotherapy." | 7.81 | Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. ( Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG, 2015) |
"Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)." | 7.79 | Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013) |
"The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer." | 7.79 | Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013) |
"To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R), in biliary tract cancer (BTC), since this disease is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy." | 7.76 | Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. ( Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S, 2010) |
"The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 7.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
"Despite the frequent clinical use of 5-fluorouracil (5-FU) in combination with radiotherapy for patients with biliary tract cancers, data remain scarce concerning specifically the influence of 5-FU on the sensitivity of these cancer cells to radiation." | 7.70 | Enhanced radiation killing by 5-fluorouracil of biliary tract cancer cell lines. ( Fukao, K; Little, JB; Moon, Y; Ohno, T; Todoroki, T, 2000) |
"We describe a patient with an intrahepatic biliary hamartoma associated with transformation to undifferentiated carcinoma which responded to intrahepatic arterial floxuridine chemotherapy." | 7.70 | A cystic biliary tumour responding to regional fluorinated pyrimidine infusion. ( Allen-Mersh, TG; Burke, D; Hedayati, B; Shousha, S, 1998) |
"The development of pellagra in a patient treated with 5-fluorouracil for malignant disease is reported." | 7.68 | Pellagra secondary to 5-fluorouracil. ( Begent, RH; Dooley, JS; Ostlere, LS; Rustin, MH; Stevens, HP, 1993) |
"The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial." | 6.82 | The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022) |
"All patients had pancreatic or biliary tract cancer." | 6.78 | A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. ( Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM, 2013) |
"Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 6.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
" The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 6.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
"Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7." | 6.69 | Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000) |
"In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin." | 5.41 | A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. ( Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ, 2021) |
"Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period." | 5.38 | Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012) |
"No standard treatment is available for advanced biliary tract cancer (BTC) after first-line therapy with gemcitabine plus cisplatin (GEMCIS)." | 5.34 | Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. ( Belkouz, A; de Vos-Geelen, J; Eskens, FALM; Klümpen, HJ; Mathôt, RAA; Punt, CJA; van Gulik, TM; van Oijen, MGH; Wilmink, JW, 2020) |
"Non-resectable biliary tract cancer is associated with poor prognosis due to widespread resistance to chemotherapeutic agents and radiotherapy." | 5.32 | Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? ( Caca, K; Deininger, M; Feisthammel, J; Kreth, F; Mössner, J; Wiedmann, M, 2003) |
"Patients with metastatic adenocarcinoma of the pancreas or biliary tract, previously untreated or having received 1 cytotoxic regimen for advanced disease, were treated with gemcitabine 1000 mg/m intravenously (IV) over 100 minutes, cisplatin 35 mg/m IV over 30 minutes, and 5-FU 2400 mg/m IV over 48 hours on day 1 of a 14-day cycle." | 5.27 | A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. ( Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM, 2018) |
"We conducted a phase II trial of 5-fluorouracil and oxaliplatin combination chemotherapy as a second-line treatment in unresectable/metastatic biliary tract cancer patients who had failed gemcitabine-based chemotherapy." | 5.20 | Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. ( Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH, 2015) |
"Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects." | 5.17 | Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013) |
"This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients." | 5.16 | A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. ( Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V, 2012) |
"The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 5.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
"Many clinical trials have been conducted with gemcitabine- or 5-fluorouracil-based regimens as treatment for unresectable biliary tract cancer; however, the results remain unsatisfactory." | 5.16 | A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Sato, T; Sato, Y; Sonoda, T; Takimoto, R; Yoshida, M, 2012) |
"This multisite study sought to optimize the dosing, schedule, and administration of fixed-dose rate (FDR) gemcitabine plus capecitabine for advanced pancreatic and biliary tract cancers using an alternating-week dose schedule of both agents." | 5.16 | Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. ( Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP, 2012) |
"We conducted this phase II study in an effort to evaluate the efficacy and safety of a gemcitabine single chemotherapy as a second-line treatment for biliary tract cancer (BTC) patients who evidenced disease progression after the administration of 5-fluorouracil (5-FU)-based palliative chemotherapy." | 5.15 | Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. ( Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2011) |
"The feasibility, safety, and efficacy of planned sequential administration of docetaxel and irinotecan with 5-fluorouracil (5-FU)/leucovorin in advanced upper gastrointestinal adenocarcinoma (UGIA) are unknown." | 5.14 | An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer. ( Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D, 2010) |
"In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer." | 5.14 | Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010) |
"Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 5.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
"To evaluate the effects of palliative chemotherapy with gemcitabine plus capecitabine (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in patients with advanced biliary tract cancer." | 5.13 | Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. ( Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F, 2008) |
"This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas." | 5.13 | Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008) |
"The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer." | 5.12 | Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. ( Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS, 2007) |
" The authors evaluated 6-month survival, response, and toxicity associated with a combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA)." | 5.11 | Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. ( Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE, 2005) |
"Previous small phase II trials have demonstrated that the combination of 5-fluorouracil (5FU) and cisplatin(CDDP) could have clinical activity in metastatic biliary tract cancer." | 5.11 | A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. ( Anak, O; Baron, B; Ducreux, M; Gress, TM; Jeziorski, K; Nordlinger, B; Rougier, P; Van Cutsem, E; Van Laethem, JL; Wagener, T, 2005) |
"We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas." | 5.10 | Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002) |
"In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57." | 5.10 | Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003) |
"We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)." | 5.09 | Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001) |
"Gemcitabine-cisplatin (GP) has been regarded as standard first-line chemotherapy for advanced biliary tract cancer (BTC)." | 5.05 | Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis. ( Jin, J; Zhang, Y; Zheng, T; Zhou, L, 2020) |
"Major adjuvant therapies for biliary tract cancer (BTC) include fluorouracil, gemcitabine and chemoradiation (CRT), but the optimum regimen remains inconclusive." | 4.90 | Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. ( Braddock, M; Chen, YP; Lin, YQ; Shi, KQ; Wang, LR; You, J; Zheng, MH; Zhu, GQ; Zou, H, 2014) |
"In this multicenter retrospective cohort analysis, we identified patients with metastatic biliary tract adenocarcinoma who were treated with Nal-IRI in combination with 5-fluorouracil and folinic acid following tumor progression under standard therapy at one of the study centers between May 2016 and January 2019." | 3.96 | First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. ( Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K, 2020) |
"The aim of this retrospective study was to investigate the relationship between UGT1A1 polymorphisms and toxicities in Chinese patients with pancreatic or biliary tract cancer receiving irinotecan-containing regimens as the second- or third-line chemotherapy." | 3.81 | Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. ( Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG, 2015) |
"The primary objective of this study was to determine the activity and safety of 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine in the first-line treatment of advanced biliary tract cancer." | 3.81 | Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. ( Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G, 2015) |
"Gemcitabine/capecitabine can be given at the standard dose in patients with severe hyperbilirubinemia, though the present data suggest that gemcitabine's activity may be limited due to poor intracellular activation." | 3.80 | Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. ( Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH, 2014) |
"The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer." | 3.79 | Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013) |
"Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)." | 3.79 | Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013) |
"To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R), in biliary tract cancer (BTC), since this disease is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy." | 3.76 | Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. ( Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S, 2010) |
"The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 3.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
"We describe a patient with an intrahepatic biliary hamartoma associated with transformation to undifferentiated carcinoma which responded to intrahepatic arterial floxuridine chemotherapy." | 3.70 | A cystic biliary tumour responding to regional fluorinated pyrimidine infusion. ( Allen-Mersh, TG; Burke, D; Hedayati, B; Shousha, S, 1998) |
"Despite the frequent clinical use of 5-fluorouracil (5-FU) in combination with radiotherapy for patients with biliary tract cancers, data remain scarce concerning specifically the influence of 5-FU on the sensitivity of these cancer cells to radiation." | 3.70 | Enhanced radiation killing by 5-fluorouracil of biliary tract cancer cell lines. ( Fukao, K; Little, JB; Moon, Y; Ohno, T; Todoroki, T, 2000) |
"The development of pellagra in a patient treated with 5-fluorouracil for malignant disease is reported." | 3.68 | Pellagra secondary to 5-fluorouracil. ( Begent, RH; Dooley, JS; Ostlere, LS; Rustin, MH; Stevens, HP, 1993) |
"A phase II trial of the regimen 5-fluorouracil, doxorubicin, and mitomycin C (FAM) was conducted in 17 patients with advanced or recurrent biliary tract cancer." | 3.67 | 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. ( Harvey, JH; Schein, PS; Smith, FP, 1984) |
"The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial." | 2.82 | The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022) |
"All patients had pancreatic or biliary tract cancer." | 2.78 | A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. ( Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM, 2013) |
"Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 2.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
" Oxaliplatin in combination with leucovorin and 5-FU should be considered a feasible chemotherapy regimen for patients with recurrent/metastatic biliary tract carcinoma." | 2.73 | Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. ( Cho, JY; Jeung, HC; Lee, DK; Lee, SJ; Lim, JY; Mun, HS; Paik, YH; Yoon, DS, 2008) |
"Cholangiocarcinoma is a rare malignancy with a poor prognosis." | 2.72 | Biliary cancer: gateway to comprehensive molecular profiling. ( Sardar, M; Shroff, RT, 2021) |
"Eniluracil is an effective inactivator of dihydropyrimidine dehydrogenase (DPD)." | 2.72 | A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. ( Cohen, DP; Czito, BG; Fernando, N; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Morse, MA; Pappas, TN; Petros, WP; Tyler, DS; Yu, D, 2006) |
" Twenty four patients with advanced or metastatic biliary tumors were treated with epiadriamycin 50 mg/m2 and cisplatin 60 mg/m2 administered bolus in proper hepatic artery on day 1, combined with systemic continuous infusion of 5-fluorouracil 200 mg/m2/day, from day 1 to day 14, every 3 weeks." | 2.71 | Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study. ( Cantore, M; Carlone, N; Caudana, R; Fiorentini, G; Mambrini, A; Manni, A; Rabbi, C; Torri, T; Zamagni, D, 2003) |
" The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 2.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
"Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7." | 2.69 | Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000) |
"2 of the 7 (29%) patients with hepatoma responded." | 2.68 | Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. ( Cunningham, D; Ellis, PA; Hickish, T; Hill, A; Nicolson, M; Norman, A; O'Brien, ME, 1995) |
"The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as well as the gallbladder." | 2.55 | [Chemotherapy for Biliary Tract Cancer]. ( Woo, SM, 2017) |
"Most patients with unresectable biliary tract cancer develop obstructive jaundice, and biliary drainage is needed before any of the aforementioned treatments." | 2.48 | Role of chemotherapy in treatments for biliary tract cancer. ( Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Takasu, A, 2012) |
"The prognosis of patients with biliary tract cancer remains unsatisfactory even with surgery owing to the high recurrence rate." | 2.48 | Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. ( Konishi, M, 2012) |
"Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity." | 2.44 | [Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007) |
"The incidence of biliary tract cancer has increased markedly in Japan over the past several decades and ranks as the sixth leading cause of cancer death." | 2.41 | Chemotherapy for biliary tract cancer in Japan. ( Okusaka, T, 2002) |
"5-Fluorouracil has long been the mainstay of the treatment of pancreatic cancer, although the response rate to this agent is < 10% and the influence on survival and quality of life is negligible." | 2.40 | Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer. ( van Groeningen, CJ, 1999) |
"Capecitabine was the most common second-line chemotherapy treatment." | 1.91 | Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers. ( Abadi, S; Davies, JM; Ho, C; Mathers, B; McIntyre, C, 2023) |
"Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies." | 1.62 | SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). ( Carrato, A; Feliu, J; Garcia-Carbonero, R; Gómez-España, MA; Martín, AM; Maurel, J; Mercadé, TM; Montes, AF; Pazo-Cid, R; Vera, R, 2021) |
"Historically, biliary tract cancer (BTC) and pancreatic cancer have been treated similarly with gemcitabine alone or combined with a platinum compound." | 1.56 | A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. ( Almohamad, W; Biondani, P; Chebib, A; Ciacio, O; Gumus, Y; Haydar, M; Innominato, PF; Karaboué, A; Pittau, G; Ulusakarya, A, 2020) |
"Biliary tract cancers are rare, and surgical resection is the standard treatment at early stages." | 1.40 | Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO). ( Aktas, B; Balakan, O; Berk, V; Cinkir, Hy; Demirci, U; Helvaci, K; Kos, T; Kucukoner, M; Oztop, I; Sevinc, A; Tonyali, O; Turan, N; Unal, OU; Yildiz, R; Yilmaz, AU, 2014) |
"The prognosis of unresectable biliary tract cancer has improved recently." | 1.39 | Improvement of prognosis for unresectable biliary tract cancer. ( Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N, 2013) |
"Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period." | 1.38 | Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012) |
"Patients with cholangiocarcinoma or gallbladder cancer have poor overall prognosis and their management is often complex." | 1.36 | Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma. ( Adham, M; Bancel, B; Baulieux, J; Cassier, PA; Lombard-Bohas, C; Ponchon, T; Scoazec, JY; Souquet, JC; Thevenet, C; Walter, T, 2010) |
"Twenty-nine patients with pancreatic cancer (PC) and 43 with biliary tract cancer (BTC; 27 cases of bile duct cancer, 8 of gallbladder cancer and 8 of cancer of the papillary area) were included." | 1.35 | Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. ( Kubota, K; Sawada, T; Shimoda, M, 2009) |
"The major clinical problem was the deep venous thrombosis related to the central venous catheter, which occurred in 5 patients (17%)." | 1.33 | Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. ( Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D, 2005) |
"Non-resectable biliary tract cancer is associated with poor prognosis due to widespread resistance to chemotherapeutic agents and radiotherapy." | 1.32 | Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? ( Caca, K; Deininger, M; Feisthammel, J; Kreth, F; Mössner, J; Wiedmann, M, 2003) |
"Nine of these 18 patients had bile duct cancer, seven had gallbladder cancer, and two had cancer of the papilla of Vater." | 1.32 | [Adjuvant arterial infusion chemotherapy for patients with biliary cancer]. ( Hasuike, Y; Kashiwazaki, M; Takeda, Y; Tsujinaka, T, 2004) |
"These included 7 cases of pancreatic cancer, 2 cases of gall bladder cancer with infiltration to the liver, and 3 cases of hepatoma." | 1.27 | [Clinical study on concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after rectal administration of FT-207 suppositories for malignant diseases of the liver, biliary tract and pancreas]. ( Hasegawa, H; Takada, T; Uchiyama, K; Yasuda, H, 1985) |
Research
Studies (146)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (4.79) | 18.7374 |
1990's | 24 (16.44) | 18.2507 |
2000's | 57 (39.04) | 29.6817 |
2010's | 41 (28.08) | 24.3611 |
2020's | 17 (11.64) | 2.80 |
Authors
Authors | Studies |
---|---|
Phelip, JM | 1 |
Desrame, J | 1 |
Edeline, J | 1 |
Barbier, E | 1 |
Terrebonne, E | 1 |
Michel, P | 2 |
Perrier, H | 1 |
Dahan, L | 1 |
Bourgeois, V | 1 |
Akouz, FK | 1 |
Soularue, E | 1 |
Ly, VL | 1 |
Molin, Y | 1 |
Lecomte, T | 2 |
Ghiringhelli, F | 1 |
Coriat, R | 1 |
Louafi, S | 1 |
Neuzillet, C | 1 |
Manfredi, S | 1 |
Malka, D | 1 |
Rizzo, A | 1 |
Ricci, AD | 1 |
Brandi, G | 1 |
Yoo, C | 2 |
Cosgrove, DP | 1 |
Reese, ES | 1 |
Fulcher, NM | 1 |
Bobiak, SS | 1 |
Lamy, FX | 1 |
Allignol, A | 1 |
Boyd, M | 1 |
Mahmoudpour, SH | 1 |
Mathers, B | 1 |
Abadi, S | 1 |
Davies, JM | 1 |
McIntyre, C | 1 |
Ho, C | 1 |
Belkouz, A | 1 |
de Vos-Geelen, J | 1 |
Mathôt, RAA | 1 |
Eskens, FALM | 1 |
van Gulik, TM | 1 |
van Oijen, MGH | 1 |
Punt, CJA | 1 |
Wilmink, JW | 1 |
Klümpen, HJ | 1 |
Kim, RD | 1 |
McDonough, S | 1 |
El-Khoueiry, AB | 1 |
Bekaii-Saab, TS | 1 |
Stein, SM | 1 |
Sahai, V | 1 |
Keogh, GP | 1 |
Kim, EJ | 2 |
Baron, AD | 1 |
Siegel, AB | 1 |
Barzi, A | 1 |
Guthrie, KA | 1 |
Javle, M | 1 |
Hochster, H | 1 |
Sinn, M | 3 |
Wege, H | 1 |
Stein, A | 1 |
Ma, WJ | 1 |
Jin, YW | 1 |
Wu, ZR | 1 |
Yang, Q | 1 |
Wang, JK | 1 |
Liu, F | 1 |
Shi, YJ | 1 |
Li, QS | 1 |
Cheng, NS | 1 |
Ulusakarya, A | 1 |
Karaboué, A | 1 |
Ciacio, O | 1 |
Pittau, G | 1 |
Haydar, M | 1 |
Biondani, P | 1 |
Gumus, Y | 1 |
Chebib, A | 1 |
Almohamad, W | 1 |
Innominato, PF | 1 |
Taghizadeh, H | 1 |
Unseld, M | 1 |
Schmiderer, A | 1 |
Djanani, A | 1 |
Wilthoner, K | 1 |
Buchinger, D | 1 |
Prager, GW | 1 |
Zheng, T | 1 |
Jin, J | 1 |
Zhou, L | 1 |
Zhang, Y | 1 |
Dee, EC | 1 |
Freret, ME | 1 |
Horick, N | 1 |
Raldow, AC | 1 |
Goyal, L | 1 |
Zhu, AX | 2 |
Parikh, AR | 1 |
Ryan, DP | 1 |
Clark, JW | 1 |
Allen, JN | 1 |
Ferrone, CR | 1 |
Fernandez-Del Castillo, C | 1 |
Tanabe, KK | 1 |
Drapek, LC | 1 |
Hong, TS | 1 |
Qadan, M | 1 |
Wo, JY | 1 |
Sardar, M | 1 |
Shroff, RT | 1 |
Gómez-España, MA | 1 |
Montes, AF | 1 |
Garcia-Carbonero, R | 1 |
Mercadé, TM | 1 |
Maurel, J | 1 |
Martín, AM | 1 |
Pazo-Cid, R | 1 |
Vera, R | 1 |
Carrato, A | 1 |
Feliu, J | 1 |
Choi, IS | 1 |
Kim, KH | 1 |
Lee, JH | 3 |
Suh, KJ | 1 |
Kim, JW | 2 |
Park, JH | 1 |
Kim, YJ | 1 |
Kim, JS | 3 |
Kim, JH | 2 |
Song, S | 1 |
Yang, W | 1 |
Tian, H | 1 |
Gong, S | 1 |
Lei, C | 1 |
Lv, K | 1 |
Lu, T | 1 |
Cheng, Q | 1 |
Yang, K | 1 |
Guo, T | 1 |
Woo, SM | 3 |
Il Yu, J | 1 |
Chul Park, H | 1 |
Hoon Lim, D | 1 |
Oh Park, J | 1 |
Suk Park, Y | 1 |
Tae Kim, S | 1 |
Ho Choi, S | 1 |
Wook Choi, D | 1 |
Woong Han, I | 1 |
Seok Heo, J | 1 |
Kaavya, J | 1 |
Mahalaxmi, I | 1 |
Devi, SM | 1 |
Santhy, KS | 1 |
Balachandar, V | 1 |
Nicolaou, A | 1 |
Gebauer, B | 1 |
Podrabsky, P | 1 |
Seehofer, D | 1 |
Ricke, J | 1 |
Dörken, B | 1 |
Riess, H | 2 |
Hildebrandt, B | 1 |
Moretto, R | 1 |
Raimondo, L | 1 |
De Stefano, A | 1 |
Cella, CA | 1 |
Matano, E | 1 |
De Placido, S | 1 |
Carlomagno, C | 1 |
Rubovszky, G | 1 |
Láng, I | 1 |
Ganofszky, E | 1 |
Horváth, Z | 1 |
Juhos, E | 1 |
Nagy, T | 1 |
Szabó, E | 1 |
Szentirmay, Z | 1 |
Budai, B | 1 |
Hitre, E | 1 |
Kaira, K | 1 |
Sunose, Y | 1 |
Ohshima, Y | 1 |
Ishioka, NS | 1 |
Arakawa, K | 1 |
Ogawa, T | 1 |
Sunaga, N | 1 |
Shimizu, K | 1 |
Tominaga, H | 1 |
Oriuchi, N | 1 |
Itoh, H | 1 |
Nagamori, S | 1 |
Kanai, Y | 1 |
Yamaguchi, A | 2 |
Segawa, A | 1 |
Ide, M | 1 |
Mori, M | 1 |
Oyama, T | 1 |
Takeyoshi, I | 1 |
Joerger, M | 1 |
Huitema, AD | 1 |
Koeberle, D | 2 |
Rosing, H | 1 |
Beijnen, JH | 1 |
Hitz, F | 1 |
Cerny, T | 1 |
Schellens, JH | 1 |
Gillessen, S | 1 |
Unal, OU | 2 |
Oztop, I | 2 |
Unek, IT | 1 |
Yilmaz, AU | 2 |
Yi, SW | 1 |
Kang, DR | 1 |
Kim, KS | 1 |
Park, MS | 2 |
Seong, J | 1 |
Park, JY | 1 |
Bang, SM | 2 |
Song, SY | 2 |
Chung, JB | 2 |
Park, SW | 1 |
Lee, WJ | 2 |
Kim, DH | 1 |
Han, SS | 2 |
Park, SJ | 3 |
Kim, TH | 3 |
Koh, YH | 2 |
Hong, EK | 2 |
Adhikaree, J | 1 |
Madhusudan, S | 1 |
Zhu, GQ | 1 |
Shi, KQ | 1 |
You, J | 1 |
Zou, H | 1 |
Lin, YQ | 1 |
Wang, LR | 1 |
Braddock, M | 1 |
Chen, YP | 1 |
Zheng, MH | 1 |
Kos, T | 1 |
Turan, N | 1 |
Kucukoner, M | 1 |
Helvaci, K | 1 |
Berk, V | 1 |
Sevinc, A | 1 |
Yildiz, R | 1 |
Cinkir, Hy | 1 |
Tonyali, O | 1 |
Demirci, U | 1 |
Aktas, B | 1 |
Balakan, O | 1 |
Hwang, IG | 3 |
Jang, JS | 2 |
Oh, SY | 3 |
Rho, MH | 2 |
Lee, S | 2 |
Park, YS | 2 |
Park, JO | 2 |
Nam, EM | 1 |
Lee, HR | 1 |
Jun, HJ | 1 |
Chi, KC | 1 |
Russolillo, N | 1 |
Ratti, F | 1 |
Viganò, L | 1 |
Langella, S | 1 |
Cipriani, F | 1 |
Aldrighetti, L | 2 |
Ferrero, A | 1 |
Petrioli, R | 1 |
Roviello, G | 1 |
Fiaschi, AI | 1 |
Laera, L | 1 |
Roviello, F | 1 |
Marrelli, D | 1 |
Francini, E | 1 |
Yang, C | 1 |
Liu, Y | 1 |
Xi, WQ | 1 |
Zhou, CF | 1 |
Jiang, JL | 1 |
Ma, T | 1 |
Ye, ZB | 1 |
Zhang, J | 1 |
Zhu, ZG | 1 |
Davis, EJ | 1 |
Griffith, KA | 1 |
Ruch, JM | 1 |
McDonnell, KJ | 1 |
Zalupski, MM | 1 |
Kim, BJ | 1 |
Kim, KP | 1 |
Hyung, J | 1 |
Ryoo, BY | 1 |
Chang, HM | 1 |
Lim, JY | 1 |
Jeung, HC | 1 |
Mun, HS | 1 |
Lee, DK | 2 |
Paik, YH | 2 |
Lee, SJ | 2 |
Yoon, DS | 2 |
Cho, JY | 2 |
Tan, BR | 1 |
Brenner, WS | 1 |
Picus, J | 1 |
Marsh, S | 1 |
Gao, F | 1 |
Fournier, C | 1 |
Fracasso, PM | 1 |
James, J | 1 |
Yen-Revollo, JL | 1 |
McLeod, HL | 1 |
Saletti, P | 1 |
Borner, M | 1 |
Gerber, D | 1 |
Dietrich, D | 1 |
Caspar, CB | 1 |
Mingrone, W | 1 |
Beretta, K | 1 |
Strasser, F | 1 |
Ruhstaller, T | 1 |
Mora, O | 1 |
Herrmann, R | 1 |
Shibata, T | 1 |
Kokubu, A | 1 |
Gotoh, M | 1 |
Ojima, H | 1 |
Ohta, T | 1 |
Yamamoto, M | 1 |
Hirohashi, S | 1 |
Kim, K | 1 |
Chie, EK | 1 |
Jang, JY | 1 |
Kim, SW | 1 |
Oh, DY | 3 |
Im, SA | 3 |
Kim, TY | 3 |
Bang, YJ | 3 |
Ha, SW | 1 |
Kim, MJ | 1 |
Lee, SH | 1 |
Kim, DW | 1 |
Heo, DS | 1 |
Berglund, A | 1 |
Byström, P | 1 |
Johansson, B | 1 |
Nygren, P | 1 |
Frödin, JE | 1 |
Pedersen, D | 1 |
Letocha, H | 1 |
Glimelius, B | 3 |
Pino, MS | 1 |
Milella, M | 1 |
Gelibter, A | 1 |
Sperduti, I | 1 |
De Marco, S | 1 |
Nuzzo, C | 1 |
Bria, E | 1 |
Carpanese, L | 1 |
Ruggeri, EM | 1 |
Carlini, P | 1 |
Cognetti, F | 1 |
Kim, BG | 1 |
Kwon, HC | 2 |
Kim, SH | 1 |
Kim, YH | 2 |
Rho, MS | 1 |
Jeong, JS | 1 |
Kim, HJ | 2 |
Pacetti, P | 2 |
Giovannetti, E | 1 |
Mambrini, A | 4 |
Nannizzi, S | 1 |
Orlandi, M | 2 |
Tartarini, R | 1 |
Del Freo, A | 2 |
Del Tacca, M | 1 |
Danesi, R | 1 |
Cantore, M | 4 |
Chen, JS | 4 |
Chao, Y | 1 |
Yang, TS | 1 |
Chou, WC | 1 |
Chen, LT | 1 |
Lee, KD | 1 |
Lin, YC | 3 |
Recchia, F | 1 |
Sica, G | 1 |
Candeloro, G | 1 |
Bisegna, R | 1 |
Bratta, M | 1 |
Bonfili, P | 1 |
Necozione, S | 1 |
Tombolini, V | 1 |
Rea, S | 1 |
Shimoda, M | 1 |
Sawada, T | 1 |
Kubota, K | 1 |
Wolf, S | 1 |
Lorenz, J | 1 |
Mössner, J | 3 |
Wiedmann, M | 3 |
Cereda, S | 1 |
Passoni, P | 1 |
Reni, M | 1 |
Viganò, MG | 1 |
Nicoletti, R | 1 |
Villa, E | 1 |
Jeong, CY | 1 |
Hong, SC | 1 |
Ha, CY | 1 |
Lee, GW | 1 |
Kang, JH | 1 |
Cassier, PA | 1 |
Thevenet, C | 1 |
Walter, T | 1 |
Baulieux, J | 1 |
Scoazec, JY | 1 |
Bancel, B | 1 |
Adham, M | 1 |
Souquet, JC | 1 |
Ponchon, T | 1 |
Lombard-Bohas, C | 1 |
Gunnlaugsson, A | 1 |
Anderson, H | 1 |
Lind, P | 1 |
Johnsson, A | 1 |
Muneoka, K | 1 |
Shirai, Y | 1 |
Sasaki, M | 2 |
Wakai, T | 1 |
Sakata, J | 1 |
Kanda, J | 1 |
Wakabayashi, H | 1 |
Hatakeyama, K | 1 |
Ko, AH | 1 |
Espinoza, AM | 1 |
Jones, KA | 1 |
Venook, AP | 1 |
Bergsland, EK | 1 |
Kelley, RK | 1 |
Dito, E | 1 |
Ong, A | 1 |
Hanover, CS | 1 |
Coakley, FV | 1 |
Tempero, MA | 1 |
Kawashima, R | 1 |
Abei, M | 1 |
Fukuda, K | 1 |
Nakamura, K | 1 |
Murata, T | 1 |
Wakayama, M | 1 |
Seo, E | 1 |
Hasegawa, N | 1 |
Mizuguchi, H | 1 |
Obata, Y | 1 |
Hyodo, I | 1 |
Hamada, H | 1 |
Yokoyama, KK | 1 |
Hayashi, T | 1 |
Ishiwatari, H | 1 |
Yoshida, M | 1 |
Sato, T | 3 |
Miyanishi, K | 1 |
Sato, Y | 3 |
Kobune, M | 1 |
Takimoto, R | 1 |
Sonoda, T | 1 |
Kato, J | 1 |
Konishi, M | 1 |
Santini, D | 1 |
Virzi, V | 1 |
Vasile, E | 1 |
Vincenzi, B | 1 |
Catalano, V | 1 |
Graziano, F | 1 |
Masi, G | 1 |
Bronte, G | 1 |
Russo, A | 1 |
Falcone, A | 1 |
Tonini, G | 1 |
Jensen, LH | 1 |
Lindebjerg, J | 1 |
Ploen, J | 1 |
Hansen, TF | 1 |
Jakobsen, A | 1 |
Hashimoto, A | 1 |
Nishiofuku, H | 1 |
Tanaka, T | 1 |
Sho, M | 1 |
Anai, H | 1 |
Nakajima, Y | 1 |
Kichikawa, K | 1 |
Furuse, J | 2 |
Kasuga, A | 1 |
Takasu, A | 1 |
Kitamura, H | 1 |
Nagashima, F | 1 |
Lim, KH | 1 |
Han, SW | 1 |
Novarino, AM | 1 |
Satolli, MA | 1 |
Chiappino, I | 2 |
Giacobino, A | 1 |
Napoletano, R | 1 |
Ceccarelli, M | 1 |
Ciccone, G | 1 |
Schena, M | 1 |
Bertetto, O | 1 |
Ciuffreda, L | 1 |
Kim, HB | 1 |
Park, JW | 1 |
Kim, CM | 1 |
Bischoff, S | 1 |
Nehls, O | 3 |
Pelzer, U | 1 |
von Weizsäcker, F | 1 |
Kubicka, S | 1 |
Stieler, JM | 1 |
Caca, K | 3 |
LoConte, NK | 1 |
Holen, KD | 1 |
Schelman, WR | 1 |
Mulkerin, DL | 1 |
Deming, DA | 1 |
Hernan, HR | 1 |
Traynor, AM | 1 |
Goggins, T | 1 |
Groteluschen, D | 1 |
Oettel, K | 1 |
Robinson, E | 1 |
Lubner, SJ | 1 |
Sasaki, T | 1 |
Isayama, H | 1 |
Nakai, Y | 1 |
Takahara, N | 1 |
Sasahira, N | 1 |
Kogure, H | 2 |
Mizuno, S | 1 |
Yagioka, H | 1 |
Ito, Y | 1 |
Yamamoto, N | 1 |
Hirano, K | 1 |
Toda, N | 1 |
Tada, M | 1 |
Omata, M | 1 |
Koike, K | 1 |
Taïeb, J | 1 |
Mitry, E | 1 |
Boige, V | 1 |
Artru, P | 1 |
Ezenfis, J | 1 |
Clavero-Fabri, MC | 2 |
Vaillant, JN | 1 |
Rougier, P | 3 |
Ducreux, M | 3 |
Klump, B | 2 |
Arkenau, HT | 1 |
Hass, HG | 2 |
Greschniok, A | 1 |
Gregor, M | 2 |
Porschen, R | 1 |
Kliche, KO | 1 |
Kubsch, K | 1 |
Raida, M | 1 |
Masri-Zada, R | 1 |
Höffken, K | 1 |
Boxberger, F | 1 |
Jüngert, B | 1 |
Brueckl, V | 1 |
Brueckl, WM | 1 |
Hautmann, M | 1 |
Hohenberger, W | 1 |
Hahn, EG | 1 |
Wein, A | 1 |
Okusaka, T | 4 |
Murad, AM | 1 |
Guimarães, RC | 1 |
Aragão, BC | 1 |
Rodrigues, VH | 1 |
Scalabrini-Neto, AO | 1 |
Padua, CA | 1 |
Moore, FC | 1 |
Morizane, C | 2 |
Okada, S | 3 |
Ueno, H | 2 |
Saisho, T | 1 |
WEISS, AJ | 1 |
JACKSON, L | 1 |
Kreth, F | 1 |
Feisthammel, J | 2 |
Deininger, M | 1 |
Kornek, GV | 2 |
Schuell, B | 1 |
Laengle, F | 1 |
Gruenberger, T | 1 |
Penz, M | 1 |
Karall, K | 1 |
Depisch, D | 1 |
Lang, F | 2 |
Scheithauer, W | 2 |
Hsu, C | 1 |
Shen, YC | 1 |
Yang, CH | 1 |
Yeh, KH | 1 |
Lu, YS | 1 |
Hsu, CH | 1 |
Liu, HT | 1 |
Li, CC | 1 |
Wu, CY | 1 |
Cheng, AL | 1 |
Enjoji, M | 1 |
Yamaguchi, K | 1 |
Nakamuta, M | 1 |
Nakashima, M | 1 |
Kotoh, K | 1 |
Tanaka, M | 1 |
Nawata, H | 1 |
Watanabe, T | 1 |
Takeda, Y | 1 |
Hasuike, Y | 1 |
Kashiwazaki, M | 1 |
Tsujinaka, T | 1 |
Alberts, SR | 1 |
Al-Khatib, H | 1 |
Mahoney, MR | 1 |
Burgart, L | 1 |
Cera, PJ | 1 |
Flynn, PJ | 1 |
Finch, TR | 1 |
Levitt, R | 1 |
Windschitl, HE | 1 |
Knost, JA | 1 |
Tschetter, LK | 1 |
Van Cutsem, E | 1 |
Van Laethem, JL | 2 |
Gress, TM | 1 |
Jeziorski, K | 1 |
Wagener, T | 1 |
Anak, O | 1 |
Baron, B | 1 |
Nordlinger, B | 1 |
Fiorentini, G | 3 |
Rabbi, C | 2 |
Zamagni, D | 2 |
Caudana, R | 2 |
Pennucci, C | 1 |
Sanguinetti, F | 1 |
Lombardi, M | 1 |
Nicoli, N | 1 |
Rao, S | 1 |
Cunningham, D | 3 |
Hawkins, RE | 1 |
Hill, ME | 1 |
Smith, D | 1 |
Daniel, F | 1 |
Ross, PJ | 2 |
Oates, J | 2 |
Norman, AR | 2 |
Chang, YS | 1 |
Yu, JS | 1 |
Uchida, S | 1 |
Nokita, H | 1 |
Horiuchi, H | 1 |
Hisaka, T | 1 |
Ishikawa, H | 1 |
Kawashima, Y | 1 |
Fujishita, M | 1 |
Kinoshita, H | 2 |
Aoyagi, S | 1 |
Shirouzu, K | 1 |
Park, SH | 1 |
Park, YH | 1 |
Lee, JN | 1 |
Cho, EK | 1 |
Shin, DB | 1 |
Nakamura, N | 1 |
Teramoto, K | 1 |
Arii, S | 1 |
Ikeda, M | 1 |
Czito, BG | 1 |
Hong, TJ | 1 |
Cohen, DP | 1 |
Petros, WP | 1 |
Tyler, DS | 1 |
Pappas, TN | 1 |
Yu, D | 1 |
Lee, CG | 1 |
Lockhart, AC | 1 |
Morse, MA | 1 |
Fernando, N | 1 |
Hurwitz, HI | 1 |
de Aretxabala, X | 1 |
Roa, I | 1 |
Berrios, M | 1 |
Hepp, J | 1 |
Gallardo, J | 1 |
Cordova, A | 1 |
Roa, JC | 1 |
Leon, J | 1 |
Maluenda, F | 1 |
Carlone, N | 1 |
Manni, A | 1 |
Torri, T | 2 |
Sato, K | 1 |
Kitajima, Y | 1 |
Miyoshi, A | 1 |
Koga, Y | 1 |
Miyazaki, K | 1 |
Iyama, S | 1 |
Takahashi, Y | 1 |
Shintani, N | 1 |
Fujikawa, K | 1 |
Ohkubo, S | 1 |
Ohnuma, K | 1 |
Niitsu, Y | 1 |
Hong, YS | 1 |
Lee, J | 1 |
Lee, SC | 1 |
Choi, SH | 1 |
Heo, JS | 1 |
Lim, HY | 1 |
Kang, WK | 1 |
Ciuleanu, T | 1 |
Diculescu, M | 1 |
Hoepffner, NM | 1 |
Trojan, J | 2 |
Sailer, V | 1 |
Zalupski, M | 1 |
Herrmann, T | 1 |
Roth, A | 1 |
Chick, J | 1 |
Brock, K | 1 |
Albert, D | 1 |
Philip, PA | 1 |
Schoppmeyer, K | 1 |
Schulze, M | 1 |
Riechelmann, RP | 1 |
Townsley, CA | 1 |
Chin, SN | 1 |
Pond, GR | 1 |
Knox, JJ | 1 |
Blanchard, P | 1 |
Huguet, F | 1 |
André, T | 1 |
Harder, J | 1 |
Kummer, O | 1 |
Olschewski, M | 1 |
Otto, F | 1 |
Blum, HE | 1 |
Opitz, O | 1 |
Yonemoto, N | 1 |
Yamao, K | 1 |
Funakoshi, A | 1 |
Ohkawa, S | 1 |
Boku, N | 1 |
Tanaka, K | 1 |
Nagase, M | 1 |
Saisho, H | 1 |
Oettle, H | 1 |
Hartmann, JT | 1 |
Hofheinz, RD | 1 |
Horger, MS | 1 |
Koppenhöfer, U | 1 |
Hochhaus, A | 1 |
Stieler, J | 1 |
Hezel, AF | 1 |
Harvey, JH | 1 |
Smith, FP | 1 |
Schein, PS | 1 |
Bedikian, AY | 1 |
Valdivieso, M | 2 |
Bodey, GP | 2 |
Ellis, PA | 1 |
Norman, A | 1 |
Hill, A | 1 |
O'Brien, ME | 1 |
Nicolson, M | 1 |
Hickish, T | 1 |
Curley, SA | 2 |
Akaishi, S | 1 |
Kobari, M | 1 |
Yusa, T | 1 |
Yamanami, H | 1 |
Furukawa, T | 1 |
Matsuno, S | 1 |
Kajanti, M | 1 |
Pyrhönen, S | 2 |
Stevens, HP | 1 |
Ostlere, LS | 1 |
Begent, RH | 1 |
Dooley, JS | 1 |
Rustin, MH | 1 |
Vaughn, DJ | 1 |
Treat, J | 1 |
Takada, T | 3 |
Kato, H | 2 |
Matsushiro, T | 2 |
Nimura, Y | 1 |
Nagakawa, T | 1 |
Nakayama, T | 1 |
Yamauchi, H | 2 |
Ogata, Y | 1 |
Shimada, H | 1 |
Miyakawa, S | 1 |
Sakoda, K | 1 |
Yasuda, H | 2 |
Tsukada, K | 1 |
Yoshida, K | 2 |
Ashida, H | 1 |
Ishikawa, Y | 1 |
Kotoura, Y | 1 |
Kajiwara, T | 1 |
Watanabe, G | 2 |
Uchimura, M | 1 |
Funabiki, T | 1 |
Ikeda, S | 1 |
Patt, YZ | 2 |
Jones, DV | 1 |
Hoque, A | 1 |
Lozano, R | 1 |
Markowitz, A | 1 |
Raijman, I | 2 |
Lynch, P | 1 |
Charnsangavej, C | 1 |
Hoffman, K | 1 |
Sjödén, PO | 1 |
Jacobsson, G | 1 |
Sellström, H | 1 |
Enander, LK | 1 |
Linné, T | 1 |
Svensson, C | 1 |
Polyzos, A | 1 |
Nikou, G | 1 |
Giannopoulos, A | 1 |
Toskas, A | 1 |
Kalahanis, N | 1 |
Papargyriou, J | 1 |
Michail, P | 1 |
Papachristodoulou, A | 1 |
Webb, A | 1 |
Prendiville, J | 1 |
Jan, YY | 2 |
Wang, HM | 1 |
Chang, WC | 1 |
Liau, CT | 2 |
Fandi, A | 1 |
Villing, AL | 1 |
Fassone, F | 1 |
Fandi, L | 1 |
Zarba, J | 1 |
Armand, JP | 1 |
Hedayati, B | 1 |
Burke, D | 1 |
Shousha, S | 1 |
Allen-Mersh, TG | 1 |
Moon, Y | 2 |
Todoroki, T | 2 |
Ohno, T | 2 |
Fukao, K | 2 |
Little, JB | 2 |
Raderer, M | 1 |
Hejna, MH | 1 |
Valencak, JB | 1 |
Weinländer, GS | 1 |
Bareck, E | 1 |
Lenauer, J | 1 |
Brodowicz, T | 1 |
van Groeningen, CJ | 1 |
Higashi, S | 1 |
Kato, C | 1 |
Sakumoto, H | 1 |
Sumiyoshi, K | 1 |
Takahahsi, T | 1 |
Matsumoto, K | 1 |
Kane, T | 1 |
Sakoda, M | 1 |
Takahashi, M | 1 |
Hosono, Y | 1 |
Asano, M | 1 |
Yamamoto, A | 1 |
Eckel, F | 1 |
Lersch, C | 1 |
Assmann, G | 1 |
Schulte-Frohlinde, E | 1 |
Zanon, C | 1 |
Alabiso, O | 1 |
Grosso, M | 1 |
Buosi, R | 1 |
Clara, R | 1 |
Satolli, A | 1 |
Zai, S | 1 |
Bortolini, M | 1 |
Botta, M | 1 |
Mussa, A | 1 |
Choi, CW | 1 |
Choi, IK | 1 |
Seo, JH | 1 |
Kim, BS | 1 |
Kim, CD | 1 |
Um, SH | 1 |
Caroli-Bosc, FX | 1 |
Gay, F | 1 |
Hendlisz, A | 1 |
Forget, F | 1 |
Bleiberg, H | 1 |
Habara, K | 1 |
Ajiki, T | 1 |
Kamigaki, T | 1 |
Nakamura, T | 1 |
Kuroda, Y | 1 |
Stevenson, JP | 1 |
O'Dwyer, PJ | 1 |
Hassan, MM | 1 |
Lozano, RD | 1 |
Waugh, KA | 1 |
Hoque, AM | 1 |
Frome, AI | 1 |
Lahoti, S | 1 |
Ellis, L | 1 |
Vauthey, JN | 1 |
Schnirer, II | 1 |
Hall, SW | 1 |
Benjamin, RS | 1 |
Murphy, WK | 1 |
Kajihara, T | 1 |
Hanaue, H | 1 |
Shimizu, T | 1 |
Yamazaki, S | 1 |
Goseki, N | 1 |
Endo, M | 1 |
Minsky, BD | 1 |
Kemeny, N | 1 |
Armstrong, JG | 1 |
Reichman, B | 1 |
Botet, J | 1 |
Valtonen, M | 1 |
Abad, A | 1 |
Rosell, R | 1 |
Barnadas, A | 1 |
Carles, J | 1 |
Ribelles, N | 1 |
Solano, V | 1 |
Okazaki, N | 1 |
Tomita, T | 1 |
Tajima, T | 1 |
Ishibashi, M | 1 |
Tagaya, N | 1 |
Aoki, H | 1 |
Itoh, S | 1 |
Kadowaki, A | 1 |
Tajima, Y | 1 |
Order, SE | 1 |
Klein, JL | 1 |
Leichner, PK | 1 |
Ettinger, DS | 1 |
Kopher, K | 1 |
Finney, K | 1 |
Surdyke, M | 1 |
Leibel, SA | 1 |
Uchiyama, K | 1 |
Hasegawa, H | 1 |
Clinical Trials (15)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours[NCT02591030] | Phase 2/Phase 3 | 191 participants (Actual) | Interventional | 2015-12-15 | Completed | ||
Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma[NCT02456714] | Phase 2 | 30 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
A Randomized Phase II Study of mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line Gemcitabine Plus Cisplatin[NCT03464968] | Phase 2 | 120 participants (Actual) | Interventional | 2015-07-29 | Completed | ||
A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508] | Phase 2 | 178 participants (Actual) | Interventional | 2018-09-04 | Completed | ||
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069] | Phase 1 | 27 participants (Actual) | Interventional | 2012-04-03 | Terminated (stopped due to Equipment that was used in the study was discontinued) | ||
Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial[NCT00073905] | Phase 2 | 44 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399] | Phase 3 | 172 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma[NCT00779454] | Phase 2 | 72 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma[NCT00009893] | Phase 2 | 42 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma[NCT02548195] | Phase 3 | 286 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy[NCT01383746] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Not enough inclusion) | ||
International Registry on Cholangiocarcinoma Treatment[NCT01920503] | 40 participants (Anticipated) | Observational [Patient Registry] | 2013-07-31 | Recruiting | |||
Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703] | Phase 2 | 38 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802] | 190 participants (Anticipated) | Observational | 2016-10-06 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Number of Participants With Intrahepatic Disease Progression After Treatment With Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
Intervention | Participants (Count of Participants) |
---|---|
Treatment | 6 |
Number of Participants With Intrahepatic Recurrence After Partial Hepatectomy With Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
Intervention | Participants (Count of Participants) |
---|---|
Treatment | 1 |
Number of Participants With Post-operative Complications After Partial Hepatectomy After Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
Intervention | Participants (Count of Participants) |
---|---|
Treatment | 1 |
Reviews
22 reviews available for fluorouracil and Biliary Tract Cancer
Article | Year |
---|---|
Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers.
Topics: Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Recurrence, Local; R | 2020 |
Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2020 |
Biliary cancer: gateway to comprehensive molecular profiling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplat | 2021 |
The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bilia | 2022 |
[Chemotherapy for Biliary Tract Cancer].
Topics: Antineoplastic Agents; Bevacizumab; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycyt | 2017 |
Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Gemci | 2019 |
Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy, Adjuvant; Deoxycytidine | 2014 |
Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuv | 2012 |
Role of chemotherapy in treatments for biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisp | 2012 |
Chemotherapy for biliary tract cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2002 |
[Systemic chemotherapy with gemcitabine for advanced biliary tract carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract | 2006 |
[5 -fluoropyrimidines for treatment of biliary tract cancers].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cape | 2006 |
Chemoradiotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2006 |
[A case of recurrent biliary cystadenocarcinoma successfully treated with 5FU/CDDP systemic chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Cystadenocarcino | 2006 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2007 |
Systemic therapy for biliary tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycy | 2008 |
Systemic chemotherapy for advanced gastrointestinal cancer.
Topics: Antineoplastic Agents; Apudoma; Biliary Tract Neoplasms; Colonic Neoplasms; Drug Therapy, Combinatio | 1980 |
Update on regional treatments for hepatobiliary malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; | 1995 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as | 1996 |
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials as Topic; | 1996 |
Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Inf | 1999 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2001 |
Trials
62 trials available for fluorouracil and Biliary Tract Cancer
Article | Year |
---|---|
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytid | 2022 |
Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deo | 2020 |
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Female; Fluor | 2020 |
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Cisplatin; De | 2021 |
Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Drug Administration Schedule; Drug Ther | 2013 |
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytid | 2014 |
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; | 2015 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2018 |
Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Female; Fluoro | 2008 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2008 |
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Administration, Oral; Adult; Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2008 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2009 |
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabin | 2009 |
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Dos | 2011 |
Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2010 |
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2012 |
A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Co | 2012 |
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycy | 2012 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Diseas | 2012 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2013 |
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Ne | 2002 |
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2003 |
Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Dru | 2003 |
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2004 |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar | 2004 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress | 2005 |
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress | 2005 |
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress | 2005 |
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress | 2005 |
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Etoposide; Fem | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle | 2005 |
Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2006 |
A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Combined Modality The | 2006 |
Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary | 2003 |
Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2007 |
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract | 2007 |
Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Camptothecin; Female; F | 2007 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2007 |
Intra-arterial and systemic chemotherapy plus external hyperthermia in unresectable biliary cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2007 |
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2008 |
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hep | 1995 |
Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 1994 |
[Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxorubicin; F | 1996 |
Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neop | 1996 |
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Etoposide; Fem | 1996 |
Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Drug Administration S | 1996 |
Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.
Topics: Aged; Anorexia; Antidotes; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Bone Marrow; Di | 1998 |
Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cis | 1998 |
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1999 |
[Arterial infusion therapy with implantable port for inoperable hepatobiliary tumors].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 1999 |
Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cyclophosphami | 2000 |
Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2000 |
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2001 |
A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Dig | 2001 |
Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2001 |
[Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, | 1992 |
Other Studies
62 other studies available for fluorouracil and Biliary Tract Cancer
Article | Year |
---|---|
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer.
Topics: Biliary Tract Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin | 2022 |
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Fluorouracil; Humans; Irino | 2022 |
Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2023 |
Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capeci | 2023 |
[Biliary tract cancer: on the way to a personalized therapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisp | 2020 |
A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2020 |
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidi | 2020 |
Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation.
Topics: Bile Duct Neoplasms; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Fluorouracil; Humans; Retrospe | 2020 |
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Che | 2021 |
Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer.
Topics: Adult; Aged; Biliary Tract Neoplasms; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Fema | 2017 |
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2013 |
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biliary Tr | 2013 |
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycy | 2014 |
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2013 |
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy; Deoxycytidine; Fe | 2014 |
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabi | 2013 |
Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2014 |
The Influence of Aging on Hepatic Regeneration and Early Outcome after Portal Vein Occlusion: A Case-Control Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahep | 2015 |
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; | 2015 |
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2017 |
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; DNA, Complementary; Down | 2008 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2008 |
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2009 |
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Dihydrouracil Dehydro | 2009 |
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; | 2010 |
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2010 |
Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2010 |
[Effect of pylorus-preserving pancreaticoduodenectomy on serum levels of 5-fluorouracil during S-1 treatment for pancreaticobiliary malignancy].
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Drug Combinations; Female; Fluoroura | 2010 |
EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antimetabolites, | 2011 |
Safety and optimal management of hepatic arterial infusion chemotherapy after pancreatectomy for pancreatobiliary cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Biliary Tract Neoplasms; Chi-Squar | 2012 |
Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bi | 2012 |
Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2012 |
Improvement of prognosis for unresectable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disea | 2013 |
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxy | 2003 |
The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs.
Topics: Biliary Tract; Biliary Tract Neoplasms; Digestive System Neoplasms; Fluorouracil; Gastrointestinal T | 1961 |
Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biliary Tract Neoplasms; Cell Division; Cell Line, Tum | 2003 |
Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases.
Topics: Antigens, Neoplasm; Bile Ducts, Extrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 An | 2004 |
[Adjuvant arterial infusion chemotherapy for patients with biliary cancer].
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chem | 2004 |
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chola | 2005 |
[The hepatic artery injection chemotherapy and prostaglandin E1 administration for hepatocellular carcinoma invading the biliary tract with jaundice].
Topics: Aged; Alprostadil; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Biliary Tract Neoplasms; Cell Line, Tumor; Enzyme In | 2006 |
Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2007 |
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisp | 2007 |
5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.
Topics: Adenoma, Bile Duct; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 1984 |
[Transfer of carmofur (HCFU) to the serum, bile, pancreatic juice and pancreatic tumor tissue in the cases of peri-pancreatic head cancer].
Topics: Administration, Oral; Antineoplastic Agents; Bile; Biliary Tract Neoplasms; Fluorouracil; Humans; Pa | 1995 |
Pellagra secondary to 5-fluorouracil.
Topics: Aged; Biliary Tract Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Male; Nicotinic Acids; Pellagr | 1993 |
A cystic biliary tumour responding to regional fluorinated pyrimidine infusion.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract | 1998 |
Killing effects of 5-fluorouracil on human biliary tract cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Death; Cell Division; Dose-Response R | 1999 |
Enhanced radiation killing by 5-fluorouracil of biliary tract cancer cell lines.
Topics: Biliary Tract Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Lethal Dose 50; Radiation | 2000 |
Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; | 2000 |
High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.
Topics: Biliary Tract Neoplasms; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relati | 2001 |
Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer.
Topics: Adult; Aged; Biliary Tract Neoplasms; Bone Marrow; Carmustine; Doxorubicin; Drug Therapy, Combinatio | 1979 |
[Nutritional therapy of patient with advanced biliary tract cancer].
Topics: Biliary Tract Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Mitom | 1991 |
Extrahepatic biliary system cancer: an update of a combined modality approach.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Brach | 1991 |
Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxo | 1990 |
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bili | 1991 |
[Chemotherapy in cancers of the gallbladder and bile ducts].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cytarabine; | 1991 |
[Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile; Biliary Tract Neoplasms; Cholestasis; Fe | 1989 |
Radiolabeled antibody in the treatment of primary and metastatic liver malignancies.
Topics: Animals; Antibodies; Biliary Tract Neoplasms; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; C | 1986 |
[Clinical study on concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after rectal administration of FT-207 suppositories for malignant diseases of the liver, biliary tract and pancreas].
Topics: Biliary Tract Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Lymph Nodes; Pancreatic Neoplasms; P | 1985 |